NetScientific plc: NetScientific Invests in Next Generation, Immunotherapeutics Company, PDS Biotechnology

  • NetScientific plc: NetScientific Invests in Next Generation, Immunotherapeutics Company, PDS Biotechnology

    NetScientific (AIM: NSCI), the biomedical and healthcare technology group, today announced it has made an investment in PDS Biotechnology Corporation (‘PDS’).

    PDS is a clinical stage immunotherapy company developing a next-generation of simpler, safer and more effective immunotherapies for cancer and infectious disease. Its novel synthetic nanoparticle platform technology developed by PDS, Versamune®, activates multiple immunological mechanisms which direct the targeting of cancer and infectious disease by the immune system.

    The Company’s lead product, PDS0101, is in phase I clinical trials in the US for HPV-related cancers. PDS has licensed the Versamune® technology to Merck KGaA for use in two early stage cancer immunotherapy programmes. The company has also ongoing pre-clinical programmes for other cancers as well as pandemic influenza.

    Farad Azima, CEO, “This is an exceptional opportunity for NetScientific. As we stated in our recent results, we have been evaluating opportunities in the therapeutic space. PDS Biotechnology is at the forefront of cancer immunotherapies and by investing in the company, represents our entry into next generation therapeutics.”

    Sir Richard Sykes, Chairman added, “The groundbreaking work of PDS in developing immunotherapeutics has the potential to transform treatments for a wide range of cancers and infectious diseases. We are delighted to be supporting the Company through its next stage of development.”

    PDS-Biotech

    Comments are closed.